REGULATORY APPROVAL AND PRICE ANALYSIS OF ANTI-ANDROGEN DRUGS MARKETED IN THE UNITED STATES AND USED IN HORMONAL THERAPY IN ADVANCED PROSTATE CANCER

Alsahali S.; Alzarea A. I; Seoane-Vazquez E.; Al Yahya S.; Eguale T.

首页> 外文期刊>Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research >REGULATORY APPROVAL AND PRICE ANALYSIS OF ANTI-ANDROGEN DRUGS MARKETED IN THE UNITED STATES AND USED IN HORMONAL THERAPY IN ADVANCED PROSTATE CANCER

【24h】

REGULATORY APPROVAL AND PRICE ANALYSIS OF ANTI-ANDROGEN DRUGS MARKETED IN THE UNITED STATES AND USED IN HORMONAL THERAPY IN ADVANCED PROSTATE CANCER

机译：美国营销抗雄激素药物的监管批准和价格分析，用于晚期前列腺癌荷尔蒙治疗

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research》 |2017年第5期|共1页
作者
Alsahali S.; Alzarea A. I; Seoane-Vazquez E.; Al Yahya S.; Eguale T.;
展开▼
作者单位

MCPHS Univ Boston MA USA;

MCPHS Univ Boston MA USA;

Massachusetts Coll Pharm &

Hlth Sci Boston MA USA;

MCPHS Univ Boston MA USA;

MCPHS Univ Boston MA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类预防医学、卫生学;
关键词

相似文献

外文文献
中文文献
专利

1. REGULATORY APPROVAL AND PRICE ANALYSIS OF ANTI-ANDROGEN DRUGS MARKETED IN THE UNITED STATES AND USED IN HORMONAL THERAPY IN ADVANCED PROSTATE CANCER [J] . Alsahali S., Alzarea A. I, Seoane-Vazquez E., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2017,第5期

机译：美国营销抗雄激素药物的监管批准和价格分析，用于晚期前列腺癌荷尔蒙治疗
2. Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials [J] . Peter Iversen, Jan-Erik Damber, Anders Malmberg, Therapeutic advances in urology. . 2016,第2期

机译：Degarelix单一疗法与促黄体激素释放激素（LHRH）激动剂加抗雄激素耀斑保护在晚期前列腺癌中的比较：两项随机对照试验的分析
3. Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study [J] . Frederik Birkebaek Thomsen Acta oncologica. . 2019,第1期

机译：抗雄激素单疗法与促进的非转移前列腺癌男性的促性腺激素释放激素激动剂：基于寄存器的观察研究
4. Photodynamic therapy using hemagglutinating virus of Japan envelope (HVJ-E): a novel therapeutic approach for the treatment of hormone antagonistic prostate cancer [C] . Mizuho Inai, Masaya Yamauchi, Norihiro Honda, Optical methods for tumor treatment and detection: mechanisms and techniques in photodynamic therapy XXIV . 2015

机译：使用日本血球凝集病毒（HVJ-E）进行光动力疗法：一种治疗激素拮抗性前列腺癌的新方法
5. Emergence of metastatic hormone refractory disease in prostate cancer after anti-androgen therapy. [D] . Lee, Edmund Chun Yu. 2004

机译：抗雄激素治疗后前列腺癌中转移激素难治性疾病的出现。
6. Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials [O] . Peter Iversen, Jan-Erik Damber, Anders Malmberg, 2016

机译：Degarelix单一疗法与促黄体激素释放激素（LHRH）激动剂加抗雄激素耀斑保护在晚期前列腺癌中的比较：两项随机对照试验的分析
7. Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer : an analysis of two randomized controlled trials [O] . Iversen, Peter, Damber, Jan-Erik, Malmberg, Anders, 2016

机译：Degarelix单一疗法与促黄体激素释放激素（LHRH）激动剂加抗雄激素耀斑保护在晚期前列腺癌中的比较：两项随机对照试验的分析

REGULATORY APPROVAL AND PRICE ANALYSIS OF ANTI-ANDROGEN DRUGS MARKETED IN THE UNITED STATES AND USED IN HORMONAL THERAPY IN ADVANCED PROSTATE CANCER

著录项

相似文献

相关主题

期刊订阅